INDV 6-K
Indivior Pharmaceuticals, Inc. (INDV)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
________________________
Washington, D.C. 20549
_____________________
FORM 6-K
_____________________
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934
For the month of February 2025
Commission File Number: 001-37835
________________________________________
Indivior PLC
________________________________________
10710 Midlothian Turnpike, Suite 125
North Chesterfield, Virginia 23235
(Address of principal executive office)
_______________________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F ☒ Form 40-F ☐
EXHIBIT INDEX
| Exhibit<br>No. | Description<br>of Exhibit |
|---|---|
| 99.1 | Announcement sent<br>to the London Stock Exchange on February 04, 2025, titled<br>“Completion of Share Repurchase<br>Program”. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Indivior PLC | |
|---|---|
| Date: February 04,<br>2025 | /s/<br>Kathryn Hudson |
| Name:<br>Kathryn Hudson | |
| Title:<br>Company Secretary |
a7381v-1
Exhibit 99.1
INDIVIOR PLC (THE 'COMPANY')
Completion of Share Repurchase Program
February 4, 2025
Indivior PLC announces that the share repurchase program announced on July 25, 2024 to repurchase its ordinary shares of $0.50 each (the "Shares") for cancellation has now completed.
In aggregate, Morgan Stanley & Co. International Plc, who undertook the program on the Company's behalf, purchased 9,415,726 Shares for a total consideration of $99,996,905.29 at an average price of £8.2486 per Share.
Contact:
Jason Thompson
Vice President, Investor Relations
1-804-402-7123
Indivior PLC's Legal Entity Identifier code is 213800V3NCQTY7IED471.